The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction

• Status: Not yet recruiting
• Trial end date: 2022-09-01
• Target enrollment: 0
• Participant gender: All

Summary

300 STIMI patients with LV systolic dysfunction will be divided into two equal groups (Group I (Study arm, n=150); will receive dapagliflozin plus conventional therapy and group (II) Control arm (n=150); will receive conventional therapy only to detect an improvement in the LVEF by ≥ 5

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Assiut University
• Treatments: 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; Adrenergic beta-Antagonists; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Angiotensinogen; Aspirin; Clopidogrel; Dapagliflozin; Diuretics; Enzyme Inhibitors; Giapreza; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mineralocorticoid Receptor Antagonists; Mineralocorticoids; Ticagrelor

Criteria

Inclusion Criteria:

• 1st time STEMI within 24 hours undergoing PPCI. (Chest pain > 30 minutes and ST segment elevation in more than one lead, include the definition of MI with a reference: Third universal definition of MI. (published at ESC Clinical Practice Guidelines 2012).

• LVEF less than 50%.

• eGFR ≥20 mL/min/1.73 m2.

Exclusion Criteria:

• Patients less than 18 years old.

• T1D (Type I diabetes mellitus).

• Hemodynamically unstable.

• Cardiogenic shock (clinical syndrome of tissue hypoperfusion resulting from cardiac dysfunction).

• History of chronic symptomatic HF with a prior hHF within last year

• Patients on dialysis.

• Serious hypersensitivity to dapagliflozin (eg, anaphylaxis, angioedema).

• Pregnant or lactating women.

• Sever hepatic impairment.